STOCKWATCH: Orphan and generic drugs diverge
This article was originally published in Scrip
Executive Summary
At least two themes emerged from last week’s JP Morgan Conference in San Francisco. At the premium pricing end of the pharmaceutical market, the continuing push for orphan drugs is intensifying and at the opposite end of the market, the management of generics companies are planning how to handle the end of the patent cliff.